PMID- 35049778
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220124
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Electronic)
IS  - 2076-2615 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Jan 9
TI  - Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in 
      Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre 
      Retrospective Study.
LID - 10.3390/ani12020155 [doi]
LID - 155
AB  - In humans, mirtazapine can prevent chemotherapy-induced nausea and vomiting 
      (CINV) and improve cancer patients' quality of life (QoL). This drug is being 
      increasingly used as an appetite stimulant in cats. The hypothesis of this 
      retrospective study was that mirtazapine could reduce the incidence of CINV and 
      weight loss in feline patients affected by lymphoma. The objectives were to 
      report the use of mirtazapine transdermal ointment and assess the incidence of 
      gastrointestinal (GI) toxicity and weight loss in cats diagnosed with lymphoma 
      and receiving chemotherapy. Transdermal mirtazapine was topically administered to 
      the inner surface of the pinna (2 mg/cat/daily) for 14 days following 
      chemotherapy administration. Data recorded from 20 patients were collected. 
      Different grades of GI toxicity were shown in 8/20 (40%) patients. Body weight 
      (BW), body condition score (BCS), and muscle condition score (MCS) improved in 
      12/20 (60%), 6/20 (30%), and 2/20 (10%) cats, respectively. Mirtazapine-induced 
      adverse events (AEs) occurred in 4/20 (20%) cats and did not require mirtazapine 
      discontinuation. Substantial weight loss was not encountered, suggesting that 
      patients had an adequate food intake after chemotherapy administration. 
      Transdermal mirtazapine ointment was considered safe and well tolerated.
FAU - Ferro, Livia
AU  - Ferro L
AUID- ORCID: 0000-0002-9382-7132
AD  - Anicura Istituto Veterinario Novara, 28060 Granozzo con Monticello, Italy.
FAU - Ciccarelli, Stefano
AU  - Ciccarelli S
AUID- ORCID: 0000-0003-4487-5784
AD  - Department of Veterinary Medicine, University of Bari "Aldo Moro", 370100 
      Valenzano, Italy.
FAU - Stanzani, Giacomo
AU  - Stanzani G
AD  - Dick White Referrals, Cambridgeshire CB8 0UH, UK.
FAU - Nappi, Lisa
AU  - Nappi L
AD  - Anicura Centro Oncologico Veterinario, 40037 Sasso Marconi, Italy.
FAU - Angelini, Francesca
AU  - Angelini F
AD  - Anicura Clinica Veterinaria CMV, 21100 Varese, Italy.
FAU - Leo, Chiara
AU  - Leo C
AUID- ORCID: 0000-0002-8700-2230
AD  - Anicura Istituto Veterinario Novara, 28060 Granozzo con Monticello, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220109
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC8772540
OTO - NOTNLM
OT  - anti-emetic
OT  - cancer
OT  - chemotherapy
OT  - feline
OT  - mirtazapine
OT  - toxicity
OT  - transdermal
COIS- The authors declare no conflict of interest.
EDAT- 2022/01/21 06:00
MHDA- 2022/01/21 06:01
PMCR- 2022/01/09
CRDT- 2022/01/20 12:26
PHST- 2021/11/29 00:00 [received]
PHST- 2022/01/04 00:00 [revised]
PHST- 2022/01/07 00:00 [accepted]
PHST- 2022/01/20 12:26 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/21 06:01 [medline]
PHST- 2022/01/09 00:00 [pmc-release]
AID - ani12020155 [pii]
AID - animals-12-00155 [pii]
AID - 10.3390/ani12020155 [doi]
PST - epublish
SO  - Animals (Basel). 2022 Jan 9;12(2):155. doi: 10.3390/ani12020155.